Please share the exact information with us. Who reported the metric, based on what study, etc. Reporting average life span of 160 months after relapse is a very significant statement that needs more information behind it.
While it sounds very positive for us, it could lull people into inaction if they aren't aware of the conditions that brought about this newly disclosed survival metric.
Is this broken down by Gleason, stage, or PSA at dx; low, intermediate, and high risk at dx; dependent on type of initial and salvage therapy? I am looking for great news and more effective treatments, but it would be good to have some "meat on the bone".
I would also be interested in you reporting the most significant "take aways" you brought back from the conference. A new thread could be devoted to your experience and what you learned.
PSA 59 on 8-26-2010 age 60. Biopsy 9-8-2010 12/12 positive, 20-80% involved, PNI in 3 cores, G 3+3,3+4,and 4+3=G7, T2b.
Eligard shot and daily Jalyn started on 10-7-2010.
IMRT to prostate and lymph nodes 25 fractions started on 11-8-2010
HDR Brachytherapy December 6 and 13, 2010.
PSA <.1 and T 23 on 2-3-2011.
PSA <.1 on 4-7-2011
Second Eligard shot on 4-7-2011
PSA <.1 and T <3 on 7-15-2011